Literature DB >> 9325475

Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease.

J Kálmán1, A Juhász, G Laird, P Dickens, T Járdánházy, A Rimanóczy, I Boncz, W L Parry-Jones, Z Janka.   

Abstract

INTRODUCTION: Inflammatory processes are suspected in the pathomechanism of Alzheimer's dementia (AD) but the serum and cerebrospinal fluid (CSF) levels of inflammatory cytokines are not yet determined in the different forms of the disorder. SUBJECTS AND METHODS: Interleukin-6 (IL-6) levels were examined in the sera and CSF of patients with mild-moderate and severe stage of late onset sporadic type of AD and in the sera of demented Down syndrome (DS) probands with similar stages of AD and compared with data of age-matched healthy controls.
RESULTS: Normal serum IL-6 levels were found in the mild-moderate stage, but significantly increased levels were found in the severe stage of both dementia groups. The CSF concentrations remained within the normal range in all groups. Positive correlations between the serum IL-6 levels and age and the severity of the disease were present.
CONCLUSION: These findings suggest a disease stage dependent general activation of the immune system both in sporadic AD and in DS with AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9325475     DOI: 10.1111/j.1600-0404.1997.tb00275.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  34 in total

Review 1.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

Review 2.  Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.

Authors:  Anders Lönneborg
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 3.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

Review 4.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

5.  Purkinje neuron physiology is altered by the inflammatory factor interleukin-6.

Authors:  Donna L Gruol; Thomas E Nelson
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

6.  Associations Between Serum Inflammatory Markers and Hippocampal Volume in a Community Sample.

Authors:  Mike F Schmidt; Kevin B Freeman; Beverly G Windham; Michael E Griswold; Iftikhar J Kullo; Stephen T Turner; Thomas H Mosley
Journal:  J Am Geriatr Soc       Date:  2016-08-22       Impact factor: 5.562

Review 7.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

8.  Systemic inflammation and cerebral palsy risk in extremely preterm infants.

Authors:  Karl C K Kuban; T Michael O'Shea; Elizabeth N Allred; Nigel Paneth; Deborah Hirtz; Raina N Fichorova; Alan Leviton
Journal:  J Child Neurol       Date:  2014-03-18       Impact factor: 1.987

Review 9.  Cerebrospinal fluid and blood biomarkers in Alzheimer's disease.

Authors:  Christian Humpel; Tanja Hochstrasser
Journal:  World J Psychiatry       Date:  2011-12-31

Review 10.  Forgot to Exercise? Exercise Derived Circulating Myokines in Alzheimer's Disease: A Perspective.

Authors:  Rajesh Gupta; Rizwan Khan; Constanza J Cortes
Journal:  Front Neurol       Date:  2021-06-30       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.